China rejected US trade overtures Thursday, demanding all tariffs be lifted and denying any progress in talks. "The US should ...

Reuters reported that the first plane, which was meant for China's Xiamen Airlines and was painted with Xiamen's logo, landed at ... suggest that many companies will pull their guidance, as ...

Rumours of Trump’s new levy dragged FTSE 100 pharma stocks into the ... when or how much he plans to tariff pharma imports. European pharma companies have called on President of the European ...

Pharmaceutical imports became the latest target for President Donald Trump’s tariffs, sending FTSE 100 drugmakers stock into ... when or how much he plans to tariff pharma imports. European pharma ...

(Photo by Andy Buchanan – WPA Pool /Getty Images) FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker.

FTSE 100 pharmaceutical giants GSK and Astrazeneca may have avoided ... industry" presents "some perceived risk to near-term guidance" for major pharmaceutical companies. In a positive turn, GSK ...

PARIS, April 15 (Reuters) - Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Pharma (CPRX – Research Report), Ascendis Pharma (ASND – Research Report) and Avanos ...

For instance, if tariffs are applied at a fixed rate across all the countries, Indian pharma companies could have an edge because of their cost advantage. India accounts for about 50% of generics ...

No. 9 / 2025Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate ...

The US is India’s largest export market for pharmaceutical goods, so the exemption brings huge relief to Indian pharma companies, which supply more than 45% of generics and 15% of biosimilars ...

Many major Indian pharmaceutical companies, including Dr Reddy's, Sun Pharma, and Aurobindo, derive 40-45% of their revenues from the US market, making them particularly vulnerable to any adverse ...